Sunshine Biopharma Inc. - SBFM STOCK NEWS

Aegis Capital Corp. acted as the sole bookrunner for Sunshine Biopharma Inc.'s $8 million underwritten public offering, aimed at supporting the development of its COVID-19 therapeutic SBFM-PL4 and anticancer compound Adva-27a. Sunshine Biopharma is focused on creating treatments for COVID-19 and aggressive forms of cancer, including pancreatic cancer. The company is moving forward with clinical trials for Adva-27a, which has shown effectiveness against multidrug-resistant cancer cells. This offering could potentially enhance Sunshine Biopharma's financial position as it seeks to progress its research and development initiatives.

Sunshine Biopharma announced the completion of its public offering of 1,882,353 units at $4.25 each, raising $8 million in gross proceeds. Each unit comprises one share of common stock and two warrants, both exercisable at $4.25. Aegis Capital Corp. managed the offering and was granted a 45-day option to purchase additional securities. The company is advancing SBFM-PL4, a lead compound for COVID-19 treatment, and preparing for clinical trials of Adva-27a, an anticancer drug targeting multidrug-resistant cancer cells.

Sunshine Biopharma, focused on oncology and antiviral drug development, has priced its public offering of 1,882,353 units at $4.25 each, totaling $8 million. Each unit comprises one share of common stock and two warrants, immediately separable for trading. Aegis Capital is the sole book-running manager and holds a 45-day option for an additional 15% of shares and warrants. The offering will close around February 17, 2022. Sunshine Biopharma's common stock and warrants have been approved for listing on the Nasdaq under symbols SBFM and SBFMW.

On December 20, 2021, Sunshine Biopharma (SBFM) issued 2,904,833 shares of Common Stock to RB Capital, converting $1,361,000 in convertible debt at an average price of $0.47 per share. The remaining convertible debt totals $1,900,000 at an average conversion price of $0.30, with maturity dates in 2023. This move is expected to enhance the company's financial position while conserving cash for ongoing research in antiviral and anticancer drug development. Key projects include SBFM-PL4, a potential COVID-19 treatment, and Adva-27a, targeting multidrug-resistant cancers.

Sunshine Biopharma (OTC PINK: SBFM) has expanded its board from three to five members by appointing three new independent directors: Andrew Tesley, JD Kish, and Dr. Rabi Kiderchah. This strategic move is part of the company's application process to uplist to Nasdaq. The new directors bring valuable expertise in legal, accounting, and medical fields. Mr. Camille Sebaaly has resigned as a director but will continue as CFO. Sunshine Biopharma is advancing treatments for COVID-19 and cancer, including ongoing studies on potential inhibitors of SARS-CoV-2 and the anticancer drug Adva-27a.

Sunshine Biopharma (SBFM) has filed a patent application for a novel treatment targeting neurodegenerative disorders. This application, dated October 1, 2021, presents data indicating that specific mRNA molecules can protect neuronal cells from oxidative stress, a condition mimicking neuronal degeneration. Neurodegenerative diseases affect millions globally, with no known cures. The company aims to develop a therapeutic approach that could potentially alleviate symptoms and halt disease progression.

Sunshine Biopharma (SBFM) announced significant advancements in its drug development for COVID-19 and cancer therapies. The company mapped mutations from Delta and other variants, finding that most mutations affect the Spike protein, leaving their PLpro inhibitors likely effective against ongoing variants. The lead compound, SBFM-PL4, is being tested in mice engineered to be susceptible to SARS-CoV-2. Additionally, Sunshine Biopharma is progressing with Adva-27a, an anticancer compound, demonstrating effectiveness against multidrug-resistant cancer cells. Clinical trials for pancreatic cancer are planned.

Sunshine Biopharma (SBFM) has launched an official Twitter account (@SunshineBio1) to enhance communication with shareholders, following feedback regarding preferred engagement methods. The company aims to utilize this platform for timely updates, recognizing the importance of transparency in modern information dissemination. Sunshine Biopharma is advancing potential Covid-19 treatments and developing the anticancer compound Adva-27a. While the company emphasizes shareholder engagement, it also acknowledges the inherent risks and uncertainties in meeting financial expectations and achieving profitability.

Sunshine Biopharma (SBFM) has secured $900,000 in additional funding from RB Capital Partners, bringing total investments to over $3.5 million. This convertible debt has a conversion price of $0.30 per share. The funds will boost the development of its COVID-19 protease inhibitor and the anticancer drug Adva-27a. The company is advancing treatments targeting SARS-CoV-2 and is preparing for clinical trials related to pancreatic cancer at McGill University. Despite the progress, Sunshine Biopharma cautions of various risks impacting growth and profitability.